title: Preparing for phase II/III HIV vaccine trials in Africa.
abstract: Before performing phase II/III clinical trials in Africa, preliminary studies, including assessment and building up of clinical and laboratory infrastructures, estimates of human immunodeficiency virus incidence, investigation of the background immune response, and evaluation of the cross-clade immune response, need to be done. Plans and ongoing work in the context of the AIDS Vaccine Integrated Project and some preliminary data are presented.
authors.affiliation: Perinatal HIV Research Unit, University of the Witwatersrand, PO Box 114, Diepkloof 1864, Johannesburg, South Africa. vardase@mweb.co.za
authors.forename: Eftyhia
authors.initials: E
authors.lastname: Vardas
authors.forename: Stefano
authors.initials: S
authors.lastname: Buttò
authors.forename: Richard
authors.initials: R
authors.lastname: Glashoff
authors.forename: Mauro S
authors.initials: MS
authors.lastname: Malnati
authors.forename: Guido
authors.initials: G
authors.lastname: Poli
authors.forename: Mario
authors.initials: M
authors.lastname: Clerici
mesh_terms: D016915:AIDS Vaccines / Q000276:immunology; D000349:Africa / Q000453:epidemiology; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D006678:HIV / Q000276:immunology; D015658:HIV Infections / Q000453:epidemiology / Q000276:immunology / Q000517:prevention & control* / Q000628:therapy*; D006801:Humans; D007753:Laboratories / Q000706:statistics & numerical data
chemical_list: D016915:AIDS Vaccines